Hyperactivation of Foxo1 preferentially depletes eTreg cells, which enhances CD8+ T cell function and anti-tumor immunity (200), suggesting that targeting PI3K/Akt/Foxo pathway in Treg cells could possibly break the Treg cell barrier in anti-tumor therapy. This evidence concerns the gene AKT1 and neoplasm.